p.82 抽出テキスト

study. J Atheroscler Thromb 2014; 21: 784-798. PMID: 24671110 44. 日本動脈硬化学会.動脈硬化性疾患予防ガイドライン2017年版.日本動脈硬化学会 2017. 45. Wändell PE, de Waard AM, Holzmann MJ, et al. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: A systematic review. Fam Pract 2018; 35: 383-398. PMID: 29385438 46. Brown MT, Bussell J, Dutta S, et al. Medication Adherence: Truth and Consequences. Am J Med Sci 2016; 351: 387-399. PMID: 27079345 47. Mifsud JL, Galea J, Garside J, et al. Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: A systematic review and meta-analysis. PLoS One 2020; 15: e0241193. PMID: 33175849 48. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists’ effect as team members on patient care: Systematic review and meta-analyses. Med Care 2010; 48: 923-933. PMID: 20720510 49. Mills KT, Obst KM, Shen W, et al. Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A Systematic Review and Meta-analysis. Ann Intern Med 2018; 168: 110-120. PMID: 29277852 50. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. PMID: 12556541 51. Ueki K, Sasako T, Okazaki Y, et al. J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 951- 964. PMID: 29079252 52. Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006; 92: 1752-1759. PMID: 16621883 53. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res 2008; 8: 60. PMID: 18366711 54. Sheridan SL, Viera AJ, Krantz MJ, et al. The effect of giving global coronary risk information to adults: A systematic review. Arch Intern Med 2010; 170: 230-239. PMID: 20142567 55. Willis A, Davies M, Yates T, et al. Primary prevention of cardiovascular disease using validated risk scores: A systematic review. J R Soc Med 2012; 105: 348-356. PMID: 22907552 56. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017: CD006887. PMID: 28290160 57. Tomasik T, Krzysztoń J, Dubas-Jakóbczyk K, et al. The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review. Acta Cardiol 2017; 72: 370-379. PMID: 28705107 58. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-1477. PMID: 7050440 59. Kornitzer M, Rose G. WHO European Collaborative Trial of multifactorial prevention of coronary heart disease. Prev Med 1985; 14: 272-278. PMID: 3903732 60. Meland E, Laerum E, Ulvik RJ. Effectiveness of two preventive interventions for coronary heart disease in primary care. Scand J Prim Health Care 1997; 15: 57-64. PMID: 9101627 61. Hetlevik I, Holmen J, Krüger O. Implementing clinical guidelines in the treatment of hypertension in general practice. Evaluation of patient outcome related to implementation of a computer-based clinical decision support system. Scand J Prim Health Care 1999; 17: 35-40. PMID: 10229991 62. Hanon O, Franconi G, Mourad JJ, et al. The estimation of cardiovascular risk in hypertensive patients is not modified by management of the hypertension. [Article in French] Arch Mal Coeur Vaiss 2000; 93: 943-947. PMID: 10989734 63. Montgomery AA, Fahey T, Peters TJ, et al. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000; 320: 686-690. PMID: 10710578 64. Ketola E, Mäkelä M, Klockars M. Individualised multifactorial lifestyle intervention trial for high-risk cardiovascular patients in primary care. Br J Gen Pract 2001; 51: 291-294. PMID: 11458482 65. Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 2003; 326: 251-252. PMID: 12560273 66. Wister A, Loewen N, Kennedy-Symonds H, et al. One-year follow-up

of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ 2007; 177: 859-865. PMID: 17923653 67 Prospective Studies Collaboration. Age-specific relevance of usual

blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913. PMID: 12493255 68. Fujiyoshi A, Ohkubo T, Miura K, et al. Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res 2012; 35: 947-953. PMID: 22739419 69. Ueda K, Omae T, Hasuo Y, et al. Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. J Hypertens 1988; 6: 991-997. PMID: 3221098 70. Arima H, Tanizaki Y, Kiyohara Y, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: The Hisayama study. Arch Intern Med 2003; 163: 361-366. PMID: 12578518 71. Takagi S, Saitoh S, Nakano M, et al. Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. J Hypertens 2000; 18: 139-144. PMID: 10694180 72. Nippon Data 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese ―Nippon data 80. J Hum Hypertens 2003; 17: 851-857. PMID: 14704729 73. Niiranen TJ, Asayama K, Thijs L, et al. Outcome-driven thresholds for home blood pressure measurement: International database of home blood pressure in relation to cardiovascular outcome. Hypertension 2013; 61: 27-34. PMID: 23129700 74. 日本高血圧学会高血圧治療ガイドライン作成委員会.高血圧治療ガイドライン2019.ライフサイエンス出版 2019. 75. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971-975. PMID: 9794737 76. Yamada MH, Fujihara K, Kodama S, et al. Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status. Diabetes Care 2021; 44: 2124-2131. PMID: 34035075 77. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373: 2103- 2116. PMID: 26551272 78. Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA 2016; 315: 2673-2682. PMID: 27195814 79. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967. PMID: 26724178 80. SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2021; 384: 1921- 1930. PMID: 34010531 81. Zhang W, Zhang S, Deng Y, et al. STEP Study Group. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med 2021; 385: 1268-1279. PMID: 34491661 82. Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397: 1625-1636. PMID: 33933205 83. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021; 398: 1053-1064. PMID: 34461040 84. 日本高血圧学会高血圧診療ガイド2020作成委員会.高血圧診療ガイド2020.文光堂 2020. 85. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e13-e115. PMID: 29133356 86. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J Hypertens 2015; 33: 195-211. PMID: 25485720 87. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared

with amlodipine in hypertensive patients with high cardiovascular